Angelo Ruggiero

3.1k total citations
101 papers, 1.6k citations indexed

About

Angelo Ruggiero is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, Angelo Ruggiero has authored 101 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Immunology, 54 papers in Dermatology and 17 papers in Physiology. Recurrent topics in Angelo Ruggiero's work include Psoriasis: Treatment and Pathogenesis (59 papers), Dermatology and Skin Diseases (37 papers) and Asthma and respiratory diseases (16 papers). Angelo Ruggiero is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (59 papers), Dermatology and Skin Diseases (37 papers) and Asthma and respiratory diseases (16 papers). Angelo Ruggiero collaborates with scholars based in Italy, Mexico and Germany. Angelo Ruggiero's co-authors include Matteo Megna, Gabriella Fabbrocini, Luca Potestio, Elisa Camela, Eleonora Cinelli, Fabrizio Martora, Teresa Battista, Alessia Villani, Claudio Marasca and Sara Cacciapuoti and has published in prestigious journals such as SHILAP Revista de lepidopterología, British Journal of Dermatology and Cancers.

In The Last Decade

Angelo Ruggiero

97 papers receiving 1.6k citations

Peers

Angelo Ruggiero
Luca Potestio Italy
Yoshinori Umezawa Japan
Melodie Young United States
H. Bachelez France
Mary Flack United States
Zenas Z N Yiu United Kingdom
Emily Edson‐Heredia United States
Satveer K. Mahil United Kingdom
Thomas Salko United States
Hongzhong Jin China
Luca Potestio Italy
Angelo Ruggiero
Citations per year, relative to Angelo Ruggiero Angelo Ruggiero (= 1×) peers Luca Potestio

Countries citing papers authored by Angelo Ruggiero

Since Specialization
Citations

This map shows the geographic impact of Angelo Ruggiero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Ruggiero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Ruggiero more than expected).

Fields of papers citing papers by Angelo Ruggiero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Ruggiero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Ruggiero. The network helps show where Angelo Ruggiero may publish in the future.

Co-authorship network of co-authors of Angelo Ruggiero

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Ruggiero. A scholar is included among the top collaborators of Angelo Ruggiero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Ruggiero. Angelo Ruggiero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Battista, Teresa, Vincenzo Picone, Luca Potestio, et al.. (2024). Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert Opinion on Drug Safety. 23(9). 1115–1126. 2 indexed citations
2.
Caso, Francesco, Matteo Megna, Luca Potestio, et al.. (2024). The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis. Expert Opinion on Biological Therapy. 24(8). 719–731. 3 indexed citations
3.
Megna, Matteo, et al.. (2024). Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced. Clinical and Experimental Dermatology. 49(10). 1186–1189. 1 indexed citations
4.
Potestio, Luca, et al.. (2024). Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety. 23(6). 677–685. 4 indexed citations
5.
Megna, Matteo, et al.. (2024). Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of Clinical Medicine. 13(9). 2691–2691. 6 indexed citations
6.
Megna, Matteo, Luca Potestio, Angelo Ruggiero, et al.. (2023). JAK Inhibitors in Psoriatic Disease. Clinical Cosmetic and Investigational Dermatology. Volume 16. 3129–3145. 17 indexed citations
7.
Megna, Matteo, Vincenzo Picone, Fabrizio Martora, et al.. (2023). A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab. JAAD Case Reports. 38. 123–126. 3 indexed citations
8.
Megna, Matteo, Elisa Camela, Angelo Ruggiero, et al.. (2023). Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?. Clinical Cosmetic and Investigational Dermatology. Volume 16. 1677–1690. 20 indexed citations
9.
Martora, Fabrizio, Massimiliano Scalvenzi, Angelo Ruggiero, et al.. (2023). Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina. 59(4). 801–801. 32 indexed citations
10.
Potestio, Luca, Teresa Battista, Sara Cacciapuoti, et al.. (2023). New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge. Biomedicines. 11(8). 2191–2191. 8 indexed citations
11.
Potestio, Luca, Elisa Camela, Sara Cacciapuoti, et al.. (2023). Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety. 22(11). 1003–1010. 4 indexed citations
12.
Martora, Fabrizio, Massimiliano Scalvenzi, Teresa Battista, et al.. (2023). Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clinical Cosmetic and Investigational Dermatology. Volume 16. 2525–2536. 16 indexed citations
13.
Megna, Matteo, et al.. (2023). Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. Journal of Clinical Medicine. 12(9). 3233–3233. 29 indexed citations
14.
Potestio, Luca, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, & Matteo Megna. (2023). Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature. PubMed. Volume 13. 19–26. 8 indexed citations
15.
Martora, Fabrizio, et al.. (2022). A case of linear psoriasis in a young patient with Down syndrome and review of the literature. Journal of Cosmetic Dermatology. 22(2). 686–688. 1 indexed citations
16.
Ruggiero, Angelo, Fabrizio Martora, Gabriella Fabbrocini, et al.. (2022). The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review. Clinical Cosmetic and Investigational Dermatology. Volume 15. 2785–2793. 26 indexed citations
17.
Ruggiero, Angelo, Gabriella Fabbrocini, Sara Cacciapuoti, et al.. (2021). Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis. Journal of Clinical Medicine. 10(5). 1031–1031. 23 indexed citations
18.
Villani, Alessia, Gabriella Fabbrocini, Jorge Ocampo‐Candiani, Angelo Ruggiero, & Sonia Sofìa Ocampo‐Garza. (2021). Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. Journal of the European Academy of Dermatology and Venereology. 35(7). 1485–1492. 44 indexed citations
19.
Gatta, Gianluca, Graziella Di Grezia, Vincenzo Cuccurullo, et al.. (2021). MRI in Pregnancy and Precision Medicine: A Review from Literature. Journal of Personalized Medicine. 12(1). 9–9. 35 indexed citations
20.
Tagliaferri, Pierosandro, Giampaolo Tortora, Rosario Guarrasi, et al.. (1996). Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.. PubMed. 2(1). 207–14. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luca Potestio Breakdown of academic impact, for papers by Yoshinori Umezawa Breakdown of academic impact, for papers by Melodie Young Breakdown of academic impact, for papers by H. Bachelez Breakdown of academic impact, for papers by Mary Flack Breakdown of academic impact, for papers by Zenas Z N Yiu Breakdown of academic impact, for papers by Emily Edson‐Heredia Breakdown of academic impact, for papers by Satveer K. Mahil Breakdown of academic impact, for papers by Thomas Salko Breakdown of academic impact, for papers by Hongzhong Jin
Rankless by CCL
2026